A Population-Based Analysis of Application of WHO Nomenclature in Pathology Reports of Pulmonary Neuroendocrine Tumors

ABSTRACT Neurocysticercosis is one of the most common risk factors for epilepsy but its association with drug-resistant epilepsy remains uncertain. Conjectures of an association with drug-resistant epilepsy have been fueled by reports of an association between calcific neurocysticercosis lesions (CNL) and hippocampal sclerosis (HS) from specialized epilepsy centers in Taenia solium-endemic regions. The debate arising from these reports is whether the association is causal. Evidence for the association is not high quality but sufficiently persuasive to merit further investigation with longitudinal imaging studies in population-based samples from geographically-diverse regions. The other controversial point is the choice of a surgical approach for drug-resistant epilepsy associated with CNL-HS. Three approaches have been described: standard anteromesial temporal lobectomy, lesionectomy involving a CNL alone and lesionectomy with anteromesial temporal lobectomy (for dual pathology); reports of the latter two approaches are limited. Presurgical evaluation should consider possibilities of delineating the epileptogenic zone/s in accordance with all three approaches.

Download Full-text

Rural-urban disparities in incidence and outcomes of neuroendocrine tumors: A population-based analysis of 6271 cases

Cancer ◽

10.1002/cncr.29338 ◽

2015 ◽

Vol 121 (13) ◽

pp. 2214-2221 ◽

Cited By ~ 17

Author(s):

Julie Hallet ◽

Calvin H. L. Law ◽

Paul J. Karanicolas ◽

Refik Saskin ◽

Ning Liu ◽

...

Keyword(s):

Neuroendocrine Tumors ◽

Population Based

Download Full-text

Evidence for a heritable contribution to neuroendocrine tumors of the small intestine

Endocrine Related Cancer ◽

10.1530/erc-15-0442 ◽

2015 ◽

Vol 23 (2) ◽

pp. 93-100 ◽

Cited By ~ 9

Author(s):

Deborah W Neklason ◽

James VanDerslice ◽

Karen Curtin ◽

Lisa A Cannon-Albright

Keyword(s):

Neuroendocrine Tumors ◽

Genetic Risk ◽

Population Based ◽

Shared Environment ◽

Significant Excess ◽

Degree Relative ◽

Cancer Data ◽

Non Hodgkin Lymphoma ◽

Relative Risks ◽

Definition Of

Small intestinal neuroendocrine tumors (SI-NETs) are rare tumors arising from the enterochromaffin cells of the gut. Having a first-degree relative with a SI-NET has been shown to confer a substantial risk arising from shared environment and genetics. Heritable risk was examined using a computerized genealogy linked to historical statewide cancer data. A population-based analysis of the observed familial clustering of SI-NETs was performed to assess the genetic risk in distant relatives. A test for significant excess relatedness of 384 individuals with genealogy data and histologically confirmed SI-NETs was performed by comparing pairwise relatedness of cases to 1000 sets of matched controls. Overall significant excess pairwise relatedness was found for the 384 cases (P<0.001) and was still observed when closer than first cousin relationships were ignored (P=0.041). Relative risks (RRs) for SI-NETs were estimated as a ratio of observed to expected number of SI-NET cases among each relationship class. Siblings have a 13.4-fold (P<0.0001) and parents have a 6.5-fold (P=0.143) RR, suggesting both genetic and environmental influences. The risk extends out to third-degree relatives with a 2.3-fold RR (P=0.008). Metachronous cancers were also reported in 26% of the SI-NET cases demonstrating an increased RR of colon, bladder, non-Hodgkin lymphoma, melanoma, and prostate cancers. Although SI-NETs are rare, relatives of these cases are at a significantly elevated risk of developing a SI-NET due to heritable genetic factors. Definition of the genetic risk factors will be an important tool for earlier diagnosis and better outcomes for SI-NETs.

Download Full-text

Functional status of neuroendocrine tumors among elderly patients: A large population-based study using SEER-Medicare data.

Journal of Clinical Oncology ◽

10.1200/jco.2016.34.15_suppl.4097 ◽

2016 ◽

Vol 34 (15_suppl) ◽

pp. 4097-4097 ◽

Cited By ~ 3

Author(s):

Chan Shen ◽

A. Dasari ◽

Shouhao Zhou ◽

Yiyi Chu ◽

Ying Xu ◽

...

Keyword(s):

Elderly Patients ◽

Functional Status ◽

Neuroendocrine Tumors ◽

Large Population ◽

Population Based ◽

Population Based Study ◽

Medicare Data

Download Full-text

Pancreatic neuroendocrine tumors: A population-based analysis of epidemiology and outcomes.

Journal of Clinical Oncology ◽

10.1200/jco.2017.35.4_suppl.401 ◽

2017 ◽

Vol 35 (4_suppl) ◽

pp. 401-401 ◽

Cited By ~ 3

Author(s):

Samer Alsidawi ◽

Gustavo Figueiredo Marcondes Westin ◽

Timothy J. Hobday ◽

Thorvardur Ragnar Halfdanarson

Keyword(s):

Neuroendocrine Tumors ◽

Metastatic Disease ◽

Early Stage ◽

Population Based ◽

Annual Incidence ◽

Pancreatic Neuroendocrine Tumors ◽

New Therapies ◽

Study Duration ◽

Younger Age ◽

Localized Disease

401 Background: Pancreatic neuroendocrine tumors (PNETs) are rare neoplasms comprising less than 2% of pancreatic tumors. Outcomes of PNETs vary by stage, grade, and clinical presentation. New therapies may have improved outcomes. We present an analysis of the epidemiology and prognosis of patients (pts) with PNETs evaluating a more recent period than previously reported. Methods: Using data from the SEER registry, we identified adults with PNETs between 2000 and 2013. Cases were identified using a combination of ICD-O-3 site and histology codes. The JMP and SEER*STAT 8.3.2 were used for statistical analysis. Overall survival (OS) was analyzed using the Kaplan–Meier method. The prognostic effect of variables was studied using multivariate Cox proportional hazards models. Results: We identified 5993 pts with PNETs. Over the study duration, there was an increase in the annual incidence from 0.3 to 1.2 per 100.000. This was largely explained by the increase in number of pts with localized disease. The OS for the entire cohort was 54 months (95%; CI 50-58) and 5-year OS rates in localized, locally advanced and metastatic disease were 81.7%, 62% and 26% respectively. New therapies were increasingly implemented after 2008 such as sunitinib, everolimus and capecitabine/temozolomide. OS was better for pts diagnosed after 2008 (HR 0.73; 95% CI, 0.69-0.79; P < 0.0001) and this remained significant after excluding pts with localized disease (HR 0.85; 95% CI, 0.78-0.92; P = 0.0002). Factors found to favorably affect OS included younger age, female sex, early stage, low grade, and surgery. In metastatic disease, pts who had surgery had better OS and this was significant after adjusting for possible confounders (HR 0.36; 95% CI, 0.3-0.45). Conclusions: In this large population-based study, we saw an increase in the annual incidence of PNETs mainly due to an increased number of pts with localized disease. The OS has improved over the study duration likely due to both stage migration and new therapies used in advanced disease. Younger age, female gender, low histologic grade, early stage and surgery were found to be factors that favorably affected survival. Surgery was found to be a predictor of better outcomes in metastatic disease.

Download Full-text